Avista Capital, a private equity firm, is set to invest in eMolecules, a novel and fast-growing e-procurement platform for high-value chemicals and bioreagents. Financial terms were not disclosed. "As pharma companies seek to simplify their supply chains and accelerate speed to market, eMolecules helps expedite drug discovery programs by reducing the barriers, time and costs associated with acquiring important research chemicals and biologic products. Avista is excited to support the growth potential eMolecules has demonstrated among its existing base of blue chip pharma customers, as well as its expansion into other biopharma and academic customers. Additionally, we see significant runway for the eMolecules business model in a number of critically important product areas," Sriram Venkataraman, Avista Capital Partner.